<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930683</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP180</org_study_id>
    <nct_id>NCT00930683</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma</brief_title>
  <acronym>MEDI-546</acronym>
  <official_title>A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with&#xD;
      scleroderma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of single and&#xD;
      multiple IV doses of MEDI-546 in adult subjects with scleroderma who have skin thickening in&#xD;
      an area suitable for repeat biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of MEDI-546 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.</measure>
    <time_frame>Study Day 84 for single-dose; Study Day 105 for multi-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of the study are to assess the PK, IM, and PD of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma.</measure>
    <time_frame>Study Day 84 for single-dose; Study Day 105 for multi-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.1 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.3 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>1.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>3.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>10.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>20.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects â‰¥ 18 years of age at the time of the first dose of MEDI-546;&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization (applies to covered entities in the&#xD;
             US only) obtained from the subject or subject's legal representative;&#xD;
&#xD;
          -  Must fulfill the American Rheumatism Association (American College of Rheumatology)&#xD;
             preliminary classification criteria for systemic sclerosis;&#xD;
&#xD;
          -  Has at least moderate skin thickening (score of at least 2 by modified Rodnan Total&#xD;
             Skin Score [mRTSS]) in at least one area suitable for repeat biopsy, such as arms,&#xD;
             legs, or trunk;&#xD;
&#xD;
          -  Women, unless surgically sterile (including tubal ligation) or at least 2 years&#xD;
             post-menopausal, must use an effective method of avoiding pregnancy (including oral,&#xD;
             injectable, transdermal, or implanted contraceptives, intrauterine device, diaphragm&#xD;
             with spermicide, cervical cap, abstinence, and sterile sexual partner) in addition to&#xD;
             the use of condoms (male or female condoms with spermicide) from signing of the&#xD;
             informed consent through the end of the study. Cessation of birth control after this&#xD;
             point should be discussed with a responsible physician. Men, unless surgically&#xD;
             sterile, must likewise practice 2 effective methods of birth control (condom with&#xD;
             spermicide or abstinence) and must use such precautions from Study Day 0 through the&#xD;
             end of the study;&#xD;
&#xD;
          -  Ability to complete the study period, including follow-up period through a maximum of&#xD;
             Study Day 105; and&#xD;
&#xD;
          -  Willing to forego other forms of experimental treatment during study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or reaction to any component of the MEDI-546 formulation;&#xD;
&#xD;
          -  Forced vital capacity (FVC) &lt; 60% predicted, diffusing capacity for carbon monoxide&#xD;
             (DLCO) &lt; 40% predicted, pulmonary hypertension requiring treatment with endothelin&#xD;
             receptor antagonists or prostacyclin analogues, scleroderma renal crisis within the&#xD;
             last year, or medically significant malabsorption;&#xD;
&#xD;
          -  Have received the following medications within 28 days before entry:&#xD;
&#xD;
               -  Cyclophosphamide at any dose&#xD;
&#xD;
               -  Systemic cyclosporine at any dose&#xD;
&#xD;
               -  Thalidomide at any dose&#xD;
&#xD;
               -  Hydroxychloroquine &gt; 600 mg/day&#xD;
&#xD;
               -  Mycophenolate mofetil &gt; 3 g/day&#xD;
&#xD;
               -  Methotrexate &gt; 25 mg/week&#xD;
&#xD;
               -  Azathioprine &gt; 3 mg/kg/day;&#xD;
&#xD;
          -  Have received leflunomide &gt; 20 mg/day within 6 months before entry;&#xD;
&#xD;
          -  Have received fluctuating doses of the following within 28 days before entry:&#xD;
&#xD;
               -  Antimalarials&#xD;
&#xD;
               -  Mycophenolate mofetil&#xD;
&#xD;
               -  Methotrexate&#xD;
&#xD;
               -  Leflunomide&#xD;
&#xD;
               -  Azathioprine;&#xD;
&#xD;
          -  Have received prednisone &gt; 20 mg/day or in fluctuating doses within 14 days before&#xD;
             entry;&#xD;
&#xD;
          -  Have received fluctuating doses of nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
             within 14 days before entry;&#xD;
&#xD;
          -  Treatment with any investigational drug therapy within 28 days before entry into the&#xD;
             study, B cell-depleting therapies within 12 months before entry, or biologic therapies&#xD;
             within 30 days or 5 half-lives of the biologic agent, whichever is longer, before&#xD;
             entry into the study;&#xD;
&#xD;
          -  In the investigator's opinion, evidence of clinically significant active infection,&#xD;
             including ongoing, chronic infection, within 28 days before entry;&#xD;
&#xD;
          -  A history of severe viral infection as judged by the investigators, including severe&#xD;
             infections of either cytomegalovirus (CMV) or the herpes family such as disseminated&#xD;
             herpes, herpes encephalitis, ophthalmic herpes;&#xD;
&#xD;
          -  Herpes zoster infection within 3 months before entry;&#xD;
&#xD;
          -  Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus&#xD;
             (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of&#xD;
             testing at screening;&#xD;
&#xD;
          -  Vaccination with live attenuated viruses within 28 days before entry;&#xD;
&#xD;
          -  Pregnancy (women, unless surgically sterile or at least 2 years post-menopausal, must&#xD;
             have a negative serum pregnancy test within 28 days before receiving MEDI-546 and a&#xD;
             negative urine pregnancy test on days of MEDI-546 administration before receiving&#xD;
             MEDI-546);&#xD;
&#xD;
          -  Breastfeeding or lactating women;&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  History of alcohol or drug abuse &lt; 1 year prior to entry;&#xD;
&#xD;
          -  History of cancer except basal cell carcinoma or in situ carcinoma of the cervix&#xD;
             treated with apparent success with curative therapy &gt; 1 year prior to entry;&#xD;
&#xD;
          -  History of active tuberculosis (TB) infection or latent TB infection without&#xD;
             completion of an appropriate course of treatment;&#xD;
&#xD;
          -  Newly positive TB skin test (defined as a reaction â‰¥ 10 mm in diameter if not on&#xD;
             systemic immunosuppressive medication or â‰¥ 5 mm if on systemic immunosuppressive&#xD;
             medication) without concomitant prophylactic therapy;&#xD;
&#xD;
          -  Elective surgery planned from the time of signing of the informed consent through end&#xD;
             of study;&#xD;
&#xD;
          -  At screening blood tests (within 28 days before entry), any of the following:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt; 2.5 x upper limit of the normal range (ULN),&#xD;
                  unless due to Myositis&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN&#xD;
&#xD;
               -  Creatinine &gt; 4.0 mg/dL&#xD;
&#xD;
               -  Creatinine &gt; 4.0 mg/dL&#xD;
&#xD;
               -  Neutrophils &lt; 1,500/mm3&#xD;
&#xD;
               -  Platelet count &lt; 50,000/mm3;&#xD;
&#xD;
          -  History of any disease, evidence of any current disease (other than scleroderma), any&#xD;
             finding upon physical examination, chest x-ray, or any laboratory abnormality that, in&#xD;
             the opinion of the investigator or medical monitor, may compromise the safety of the&#xD;
             subject in the study or confound the analysis of the study; or&#xD;
&#xD;
          -  Any employee of the research site who is involved with the conduct of the study.&#xD;
&#xD;
          -  History of vasculitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Yoo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

